PLIANT THERAPEUTICS
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avร6 and avร1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both ... IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avร1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
PLIANT THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical Recruiting Therapeutics
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.pliantrx.com
Total Employee:
101+
Status:
Active
Contact:
(910)509-3977
Email Addresses:
[email protected]
Total Funding:
694.95 M USD
Technology used in webpage:
Amazon HSTS IPv6 ReCAPTCHA V2 Amazon Virginia Region COVID-19 Ruby On Rails Token Envoy Akamai Hosted Comcast
Similar Organizations
4D Molecular Therapeutics
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Alzheon
Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Annexon Biosciences
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Cytosorbents
Cytosorbents develops therapeutic devices used in purifying blood to treat life-threatening diseases.
Found
Found is dedicated to improving peopleโs overall wellbeing by making evidence-based weight loss accessible and affordable.
GRO Biosciences
GRO Biosciences is a biotechnology company that expands the amino acid alphabet to overcome the limitations of protein therapeutics.
PathAI
PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Sarepta Therapeutics
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Novartis Institutes for Biomedical Research
Novartis Institutes for Biomedical Research investment in Series C - Pliant Therapeutics
Agent Capital
Agent Capital investment in Series C - Pliant Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Pliant Therapeutics
Logos Capital
Logos Capital investment in Series C - Pliant Therapeutics
Eventide
Eventide investment in Series C - Pliant Therapeutics
Schroder Adveq
Schroder Adveq investment in Series C - Pliant Therapeutics
S-Cubed Capital
S-Cubed Capital investment in Series C - Pliant Therapeutics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Pliant Therapeutics
Redmile Group
Redmile Group investment in Series C - Pliant Therapeutics
Menlo Ventures
Menlo Ventures investment in Series C - Pliant Therapeutics
Key Employee Changes
Official Site Inspections
http://www.pliantrx.com Semrush global rank: 2.61 M Semrush visits lastest month: 6.86 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pliant Therapeutics"
About - Pliant Therapeutics
We are a clinical stage biopharmaceutical company discovering and developing novel therapies for the treatment of fibrosis and related diseases. By leveraging our powerful product โฆSee details»
Overview - Pliant Therapeutics
We are pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ฮฒ1 signaling inhibition.See details»
Investors & Media - Pliant Therapeutics, Inc.
The Investor Relations website contains information about Pliant Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Press Releases - Pliant Therapeutics, Inc.
May 1, 2025 The Investor Relations website contains information about Pliant Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Pliant Therapeutics Provides Corporate Update and Reports โฆ
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release โฆSee details»
Pliant Therapeutics - LinkedIn
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. At Pliant, we โฆSee details»
Pliant Therapeutics - Craft
Pliant Therapeutics is a company focused on discovering, developing, and commercializing treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and โฆSee details»
Pliant Therapeutics, Inc. (PLRX) - Yahoo Finance
Find the latest Pliant Therapeutics, Inc. (PLRX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Pliant Therapeutics Announces Strategic Realignment of
May 1, 2025 Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations May 01, 2025 16:05 ET | Source: Pliant โฆSee details»
PLRX Stock Price | Pliant Therapeutics Inc. Stock Quote โฆ
6 days ago PLRX | Complete Pliant Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial โฆSee details»
Pliant Therapeutics - Crunchbase Company Profile & Funding
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.See details»
Pliant Therapeutics, Inc. - PharmaDepth
Overview for Pliant Therapeutics, Inc.Upcoming Patent Expirations No upcoming patent expirations foundSee details»
Pliant Therapeutics (PLRX) Company Profile & Description
Jun 3, 2020 Company profile for Pliant Therapeutics, Inc. (PLRX) stock, with a description, list of executives, contact details and other key facts.See details»
Stockwatch
Aug 7, 2025 For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this โฆSee details»
PLRX Press Release: Pliant Therapeutics Provides Corporate Update...
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook. Forward-Looking Statements Statements contained in this press release โฆSee details»
Team - Pliant Therapeutics
Pliantโs world-renowned founders have broad experience in fibrosis biology and small molecule chemistry, and highly experienced drug developers are translating this science into novel โฆSee details»
Pliant Therapeutics, Inc. Company Information - Simply Wall St
Learn more about Pliant Therapeutics, Inc. (PLRX). From their employee growth over the years and their exchange listings.See details»
Pliant Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Jun 15, 2025 Explore Pliant Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 12 clinical trials, 179 news, and 13 literature, Disease Domain ...See details»
Pliant - 2025 Company Profile - Tracxn
Aug 8, 2025 Pliant - Developer of drugs related to Fibrosis, COVID-19, and Muscular Dystrophies. Public Company. Raised a total funding of $207M over 3 rounds from 14 investors.See details»
Pliant Therapeutics Provides Corporate Update and Reports โฆ
Detailed price information for Pliant Therapeutics Inc (PLRX-Q) from The Globe and Mail including charting and trades.See details»